Apnimed (APMD) Stock Forecast: StockMap's 2-Week Call
APMD stock forecast: StockMap's model leans Underperform on Apnimed for the two weeks after the Nov 16 close, toward APMD trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on APMD since Aug 21; by chance, a call on the same dates was right 62% of the time.
Apnimed last closed at $16.28, -3.78% on the session.
Against the IVW growth benchmark the position is -1.16% over the forecast window.
Apnimed's market cap is $677.77M as of November 16, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -48 (too close to call).
Where APMD sits: sized by market cap, coloured by the day's move.
The read is built from 12 underlying insights — 2 bullish and 10 bearish.
Agreement across those insights is 83%.
37 daily calls for APMD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
Apnimed is classified under Health Care / Pharmaceuticals.
StockMap tracks Apnimed as the 69th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 76 Moderate Underperform, 47 Neutral, 29 Strong Underperform and 1 Moderate Outperform.
On that composite Apnimed ranks 113th of 153 in the group, against a group median of -0.33.